A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/3/2014 |
| Start Date: | May 2014 |
| End Date: | June 2014 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects
This is an open label, randomized, single dose, one cohort, two sequence, two period
crossover study in healthy subjects. The primary objective of the study is to evaluate the
effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single
oral dose of bosutinib in healthy subjects.
crossover study in healthy subjects. The primary objective of the study is to evaluate the
effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single
oral dose of bosutinib in healthy subjects.
Inclusion Criteria:
- Healthy male and/or female subjects with an informed consent document signed and
dated by the subject.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease
- Pregnant or nursing females; females of childbearing potential who are unwilling or
unable to use an acceptable method of non hormonal contraception as outlined in this
protocol .
- Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half lives (whichever is longer) prior to the first dose of study medication.
We found this trial at
1
site
Click here to add this to my saved trials
